ASCO 2012 LC Highlights: Dr. Joel Neal on the SELECT Trial of Tarceva (Erlotinib) As Adjuvant Therapy for EGFR Mutation-Positive Advanced NSCLC (audio)
09/16/12 • 4 min
Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer.
Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer.
Previous Episode
ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (audio)
Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
Next Episode
ASCO 2012 LC Highlights: Dr. Joel Neal on Molecular Targets in Squamous NSCLC (audio)
Dr. Joel Neal presents interesting early data demonstrating that squamous NSCLC often features identifiable molecular markers that can potentially be targeted by novel therapies.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/gracecast-lung-cancer-audio-126564/asco-2012-lc-highlights-dr-joel-neal-on-the-select-trial-of-tarceva-er-6326754"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to asco 2012 lc highlights: dr. joel neal on the select trial of tarceva (erlotinib) as adjuvant therapy for egfr mutation-positive advanced nsclc (audio) on goodpods" style="width: 225px" /> </a>
Copy